AI Engines For more Details: Perplexity Kagi Labs You
Pain Relief: Dipyrone is commonly used to relieve moderate to severe pain, such as headache, dental pain, postoperative pain, and musculoskeletal pain. It is often prescribed when other pain medications, such as non-prescription NSAIDs or opioids, are not effective or not suitable.
Fever Reduction: Dipyrone is also used to reduce fever in conditions such as infections, influenza, and other febrile illnesses. It helps lower body temperature by inhibiting the production of prostaglandins, which are involved in the body's inflammatory response.
Antispasmodic Effects: Dipyrone may have antispasmodic effects on smooth muscles, making it potentially useful in the treatment of conditions involving muscle spasms, such as colic or renal colic.
Migraine Treatment: Dipyrone has been used in some countries as an alternative treatment for migraines, either alone or in combination with other medications. It can help alleviate migraine-associated pain and reduce the intensity and duration of migraine attacks.
Acute Renal Colic: Dipyrone may be used to provide pain relief in cases of acute renal colic, a severe form of abdominal pain caused by kidney stones obstructing the urinary tract.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 0.7 | 0.7 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1 | 0.3 | 2.33 |
| Allergies | 0.5 | 0.5 | 0 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 1.1 | 1 | 0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 0.9 | 0.3 | 2 |
| Anorexia Nervosa | 0.7 | 0.6 | 0.17 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 1.3 | 0.6 | 1.17 |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 1.1 | 1.3 | -0.18 |
| Autism | 1.3 | 1.7 | -0.31 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1 | 1 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Carcinoma | 1.3 | 0.7 | 0.86 |
| Celiac Disease | 0.6 | 1 | -0.67 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 0.6 | 1.2 | -1 |
| Chronic Kidney Disease | 0.7 | 0.3 | 1.33 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.3 | 2.33 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.3 | 1.33 |
| Cognitive Function | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 1.7 | 0.3 | 4.67 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.3 | 0.3 | 0 |
| COVID-19 | 1.2 | 1.5 | -0.25 |
| Crohn's Disease | 1.4 | 0.8 | 0.75 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.1 | 0.6 | -5 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 1.4 | 1.2 | 0.17 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 1 | -2.33 |
| Endometriosis | 1 | 1 | |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.6 | 0.9 | -0.5 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.6 | 0.5 | 0.2 |
| Functional constipation / chronic idiopathic constipation | 1.1 | 1 | 0.1 |
| gallstone disease (gsd) | 0.5 | 0.5 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.3 | -2 |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.3 | 0.1 | 2 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 0.3 | 0.6 | -1 |
| Heart Failure | 1 | 1 | |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| hyperglycemia | 0.7 | 0.7 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.2 | 0.9 | 0.33 |
| Hypoxia | 0.7 | 0.3 | 1.33 |
| IgA nephropathy (IgAN) | 1 | 0.3 | 2.33 |
| Inflammatory Bowel Disease | 1.7 | 1.4 | 0.21 |
| Insomnia | 1.3 | 0.6 | 1.17 |
| Intelligence | 0.3 | 0.3 | 0 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 0.6 | 1 | -0.67 |
| ischemic stroke | 1 | 0.3 | 2.33 |
| Liver Cirrhosis | 2 | 0.9 | 1.22 |
| Long COVID | 1 | 1 | 0 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.4 | -0.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.8 | 1.3 | 0.38 |
| Mood Disorders | 1.4 | 1.2 | 0.17 |
| multiple chemical sensitivity [MCS] | 1 | 1 | |
| Multiple Sclerosis | 1.7 | 1.4 | 0.21 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.3 | 0.4 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 0.3 | 1.67 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.6 | 1.7 | -0.06 |
| obsessive-compulsive disorder | 1.1 | 0.8 | 0.38 |
| Osteoarthritis | 0.6 | 0.6 | 0 |
| Osteoporosis | 0.3 | 0.6 | -1 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2 | 0.9 | 1.22 |
| Polycystic ovary syndrome | 1.3 | 0.9 | 0.44 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 1 | 0.5 | 1 |
| Psoriasis | 0.3 | 1.1 | -2.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.6 | 0.3 | 4.33 |
| Schizophrenia | 1.3 | 0.7 | 0.86 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 1 | 0.7 | 0.43 |
| Sleep Apnea | 0.3 | -0.3 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.7 | 0.7 | 0 |
| Systemic Lupus Erythematosus | 1.3 | 1.3 | |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 0.9 | 0.6 | 0.5 |
| Type 2 Diabetes | 1.3 | 1.1 | 0.18 |
| Ulcerative colitis | 1.1 | 1.3 | -0.18 |
| Unhealthy Ageing | 0.9 | 0.4 | 1.25 |
| Vitiligo | 1.1 | 0.4 | 1.75 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
